Docetaxel Podcasts This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

JAMA Oncology : Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in ERBB2-Positive Breast Cancer
Interview with Thomas Hatschek, MD, PhD, author of Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial (Source: JAMA Specialty Journals Author Interviews)
Source: JAMA Specialty Journals Author Interviews - June 24, 2021 Category: General Medicine Authors: The JAMA Network Source Type: podcasts

TITAN Study & amp; Docetaxel: There Is Some Support To Using Apalutamide After Patients Received Docetaxel
Kim Nguyen Chi Of The University Of British Colombia Discusses TITAN Study & Docetaxel: There Is Some Support To Using Apalutamide After Patients Received Docetaxel. BACKROUND: TITAN was ... Author: Annual-Meeting Added: 06/02/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 2, 2019 Category: Cancer & Oncology Source Type: podcasts

Long-Term Management of Patients Doing Well on Immunotherapy for Advanced NSCLC: Insights from KEYNOTE-010 (BMIC-066)
Dr. Jack West reviews longitudinal outcomes for patients on the KEYNOTE-010 trial of pembrolizumab (Keytruda) vs. docetaxel as 2nd line therapy for advanced NSCLC, with helpful new info on those compl... Author: BeaconMedIC Added: 11/13/2018 (Source: Oncology Tube)
Source: Oncology Tube - November 14, 2018 Category: Cancer & Oncology Source Type: podcasts

Adjuvant Docetaxel for Intermediate or High Risk Prostate Cancer After Radiation: Highlights in GU Oncology from ASCO 2018 (BMIC-060)
Dr. Daniel Goldstein summarizes findings of a trial presented at ASCO 2018 by Dr. Kellolumpu-Lehtinen, assessing the benefit of adjuvant docetaxel for patients after radiation for patients with high o... Author: BeaconMedIC Added: 08/28/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 29, 2018 Category: Cancer & Oncology Source Type: podcasts

Benefits of using ramucirumab plus docetaxel in 2nd line NSCLC
David R. Gandara, MD, talks about the benefits of using Cyramza (ramucirumab) plus docetaxel verus docetaxel alone in 2nd line NSCLC at ASCO 2018. Author: obr Added: 07/19/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 19, 2018 Category: Cancer & Oncology Source Type: podcasts

The benefits of using ramucirumab plus docetaxel in 2nd line NSCLC
Roy S. Herbst, MD, PhD, explains the benefits of using ramucirumab plus docetaxel in 2nd line NSCLC at ASCO 2018. Author: obr Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts

Benefits of combination docetaxel + ramucirumab
Edgardo S. Santos, MD, FACP, explains the benefits of docetaxel plus ramucirumab versus docetaxel alone during 2nd line non-small cell lung cancer (NSCLC) at ASCO 2018. Author: obr Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts

Exciting advances in systemic therapy for prostate cancer: docetaxel and abiraterone
The identification of effective systemic medications for prostate cancer has been relatively recent and this field is now making exciting advances. Speaking from the British Oncology Pharmacy Associat... Author: VJOncology Added: 01/30/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 30, 2018 Category: Cancer & Oncology Source Type: podcasts

ADT + Abiraterone versus ADT + Docetaxel
Mark Wildgust, Vice President of Global Medical Affairs for Janssen Oncology explains which combination improved survival for patients with prostate cancer: androgen deprivation therapy plus abiratero... Author: ASCO2017 Added: 06/15/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 15, 2017 Category: Cancer & Oncology Source Type: podcasts

Docetaxel With or Without Plinabulin for Stage 3b or 4 Non-Small Cell Lung Cancer
Heather McArthur, MD of Cedars-Sinai Medical Center gives an overview of a poster discussion that was presented at the ASCO-SITC Symposium. This discussion described the results of a randomized study ... Author: ASCO-SITC2017 Added: 03/06/2017 (Source: Oncology Tube)
Source: Oncology Tube - March 6, 2017 Category: Cancer & Oncology Source Type: podcasts

KEYNOTE-010: Pembrolizumab versus docetaxel for advanced PD-L1-positive NSCLC
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Solange Peters, MD, PhD, from Lausanne University Hospital, Lausanne, Sw... Author: EMJ Added: 02/28/2016 (Source: Oncology Tube)
Source: Oncology Tube - February 28, 2016 Category: Cancer & Oncology Source Type: podcasts

Update from CheckMate 057: Nivolumab versus docetaxel in advanced non-squamous non-small cell lung cancer
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Johan Vansteenkiste, MD, PhD, from University of Leuven, Leuven, Belgium... Author: EMJ Added: 02/01/2016 (Source: Oncology Tube)
Source: Oncology Tube - February 1, 2016 Category: Cancer & Oncology Source Type: podcasts

Choices Among Immunotherapeutics May Be the Future of Lung Cancer Care
Novel immunotherapy agent atezolizumab (MPDL3280A) looks superior to Taxotere (docetaxel) in a study, specifically for patients with PD-L1. What are the implications of multiple agents with similar me... Author: cancergrace Added: 06/26/2015 (Source: Oncology Tube)
Source: Oncology Tube - June 26, 2015 Category: Cancer & Oncology Source Type: podcasts

Immunotherapy for Non-Squamous NSCLC: Should We be Using Biomarker Selection?
The immune checkpoint inhibitor Opdivo (nivolumab) shows better efficacy than Taxotere (docetaxel) for advanced non-squamous NSCLC, but this was seen only in patients with PD-L1 protein expression on ... Author: cancergrace Added: 06/24/2015 (Source: Oncology Tube)
Source: Oncology Tube - June 24, 2015 Category: Cancer & Oncology Source Type: podcasts

Immunotherapy for Squamous Non-Small Cell Lung Cancer
The immune checkpoint inhibitor nivolumab has been shown in the CheckMate 017 trial to lead to better response rates, survival, and better tolerability than docetaxel (Taxotere) chemotherapy. But can ... Author: cancergrace Added: 06/17/2015 (Source: Oncology Tube)
Source: Oncology Tube - June 17, 2015 Category: Cancer & Oncology Source Type: podcasts